Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with advanced lung cancer, advanced stomach cancer, advanced pancreatic cancer, liver cancer (hepatocellular carcinoma), or advanced colorectal cancer, confirmed by laboratory testing of tissue or cells
• People whose saved tumour tissue sample (preserved in a specific way called formalin-fixed, paraffin-embedded) is sufficient for a certified pathology lab to confirm the cancer diagnosis
• People whose blood test results before starting treatment fall within these ranges: haemoglobin at least 8.0 g/dL, neutrophil count at least 1×10⁹/L, lymphocyte count within the institution's normal lower limit, platelet count at least 50×10⁹/L, serum creatinine no more than 2.0 mg/dL, bilirubin no more than twice the institution's upper normal limit, and liver enzymes (AST/ALT) no more than twice the institution's upper normal limit
• People who do not experience shortness of breath while at rest, and whose blood oxygen level is 90% or higher while breathing normal room air
• People who do not have a genetic disease
• People who are capable of having children and who agree to use contraception throughout the trial; women of childbearing potential must have a negative pregnancy test within 7 days before starting treatment
• People with a Karnofsky performance score of 80% or higher, which means they are able to carry out normal activity with only minor signs or symptoms of illness (confirm with trial site)
• People who are willing and able to provide written informed consent before any study-related procedures begin
• People who agree to participate in long-term follow-up for up to 1 year if they receive the NKT cell infusion treatment

Who may not be able to join:

• People with significant organ problems, including serious heart disease, a heart attack in the past six months, unstable chest pain (angina), a coronary procedure (angioplasty) in the past six months, uncontrolled heart rhythm problems, severe liver disease (Child-Pugh Class C), kidney failure or a toxic build-up of waste in the blood (uremia), respiratory failure, impaired consciousness, or kidney failure
• People who have lymphoma or leukaemia
• People with serious infections currently requiring antibiotic treatment, or who have a bleeding disorder
• People diagnosed with myelodysplastic syndrome (MDS), a condition affecting blood cell production in the bone marrow
• People with a history of immune system deficiency or autoimmune disease
• People who test positive for HIV, Hepatitis B surface antigen, or Hepatitis C (by PCR test) within 21 days before enrolling in the trial
• People who are currently receiving chemotherapy
• People with another medical condition that would prevent them from safely undergoing the trial treatment
• People who have participated in another clinical trial involving an experimental treatment within 4 weeks before the first dose of the study treatment
• People who are pregnant or breastfeeding
• People who are unable to provide informed consent
• People who would not be available for follow-up assessments after the trial

Important: Always verify eligibility with the trial site directly before applying.